Table 1.

INSTI currently in clinical trials.

Name	Company	Structure	Anti-INa	Anti-HIVb	T1/2	Status	Ref.
Raltegravir MK-0518 Isenstress®	Merck & Co.		2–7	8.9	1; 7–12	FDA Approved October 2007	[35, 47–49]
Elvitegravir JTK-303 GS-9137	Japan Tobacco Inc. and Gilead Sciences		7	1.7	3; 9*	Phase III	[35, 47]
S/GSK-1349572	ViiV-Healthcare and Shionogi & Co. Ltd		2.7	2	14	Phase IIb	[35, 50]

^aIC₅₀ and

^bEC₉₀ are expressed in nM. Half-life of compounds (T_1/2) are expressed in h.

^*When boosted with ritonavir.